Loading...
The role of targeted therapy in the management of patients with AML
Drug therapy for acute myeloid leukemia (AML) is finally undergoing major changes in 2017. This is due to the US Food and Drug Administration’s approval of several new, targeted agents (midostaurin, enasidenib, and gemtuzumab ozogamicin). Paired with the recent approval of a novel liposomal formulat...
Na minha lista:
| Udgivet i: | Hematology Am Soc Hematol Educ Program |
|---|---|
| Hovedforfatter: | |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
American Society of Hematology
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6142552/ https://ncbi.nlm.nih.gov/pubmed/29222237 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|